Yehlisa uMngcipheko wokuFayiswa kweNtliziyo ngama-38%! I-Tirzepatide ilungisa kwakhona iMeko yoNyango lwentliziyo

I-Tirzepatide, i-novel dual receptor agonist (GLP-1 / GIP), ifumene ingqwalasela ebalulekileyo kwiminyaka yakutshanje ngendima yayo kunyango lwesifo seswekile. Nangona kunjalo, amandla ayo kwizifo ze-cardiovascular and renal ngokuthe ngcembe avela. Uphononongo lwakutsha nje lubonisa ukuba i-tirzepatide ibonisa ukusebenza kakuhle kwizigulane ezinokusilela kwentliziyo kunye neqhezu le-ejection eligciniweyo (HFpEF) kudityaniswe nokutyeba kakhulu kunye nesifo sezintso esingapheliyo (CKD). Ulingo lwezonyango lwe-SUMMIT lubonise ukuba izigulane ezifumana i-tirzepatide zine-38% yokunciphisa umngcipheko wokufa kwe-cardiovascular kufa okanye ukusilela kwentliziyo kubi kakhulu kwiiveki ezingama-52, ngelixa izikhombisi zokusebenza kwezintso ezifana ne-eGFR ziphuculwe kakhulu. Oku kufunyanisiweyo kunika indlela entsha yonyango kwizigulana ezinokuphazamiseka kwemetabolism.

Kwintsimi ye-cardiovascular, indlela yokusebenza ye-tirzepatide ihamba ngaphaya kommiselo we-metabolic. Ngokuvula zombini i-GLP-1 kunye ne-GIP receptors, inciphisa umthamo we-adipocytes, ngaloo ndlela inciphisa uxinzelelo lomatshini lwezicubu ezinamafutha entliziyweni kunye nokuphucula amandla e-myocardial metabolism kunye ne-anti-ischemic umthamo. Kwizigulane ze-HFpEF, ukutyeba kakhulu kunye nokudumba okungapheliyo ngabona banegalelo eliphambili, kwaye i-tirzepatide's dual-receptor activation icinezela ngokufanelekileyo ukukhutshwa kwe-cytokine evuthayo kunye nokunciphisa i-myocardial fibrosis, ngaloo ndlela ilibazisa ukuwohloka komsebenzi wentliziyo. Ukongezelela, iphucula umgangatho wamanqaku obomi achazwe ngesigulana (njenge-KCCQ-CSS) kunye nomthamo wokuzivocavoca.

I-Tirzepatide ikwabonisa iziphumo ezithembisayo kukhuseleko lwezintso. I-CKD ihlala ihamba kunye nokuphazamiseka kwemetabolism kunye nokudumba okuphantsi. Ichiza lisebenza ngeendlela ezimbini: ukuphucula i-glomerular hemodynamics ukunciphisa i-proteinuria, kunye nokuthintela ngokuthe ngqo inkqubo ye-renal fibrosis. Kulingo lwe-SUMMIT, i-tirzepatide yandise kakhulu amanqanaba e-eGFR asekelwe kwi-cystatin C kunye nokunciphisa i-albuminuria kungakhathaliseki ukuba izigulane zine-CKD, ebonisa ukhuseleko olubanzi lwezintso. Oku kufunyanisiweyo kuvula indlela entsha yokunyanga isifo seswekile nephropathy kunye nezinye izifo ezingapheliyo zezintso.

Okona kuphawuleka ngakumbi lixabiso elikhethekileyo le-tirzepatide kwizigulana “ezinobuthathu” bokutyeba, i-HFpEF, kunye ne-CKD-iqela elinokuxilongwa kakubi. I-Tirzepatide iphucula ukubunjwa komzimba (ukunciphisa ukuqokelelwa kwamafutha kunye nokuphucula ukusebenza kakuhle kwe-muscle metabolic) kwaye imodareyitha iindlela zokuvuvukala, ngaloo ndlela inikezela ngokhuseleko olulungelelanisiweyo kumalungu amaninzi. Njengoko iimpawu ze-tirzepatide ziqhubeka zisanda, ikulungele ukuba sisiseko sonyango kulawulo lwezifo ze-metabolic kunye ne-comorbidities.